Letter in Response to "HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety"

Am J Nephrol. 2021;52(12):977-978. doi: 10.1159/000520156. Epub 2021 Nov 2.

Authors

Hiroyasu Yamamoto¹, Kiyoshi Nobori², Yoshimi Matsuda², Yasuhiro Hayashi³, Takanori Hayasaki³, Tadao Akizawa⁴

Affiliations

¹ Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
² Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
³ Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan.
⁴ Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

PMID: 34727543
DOI: 10.1159/000520156

No abstract available

Publication types

Letter
Comment

MeSH terms

Anemia*
Humans
Hypoxia-Inducible Factor-Proline Dioxygenases
Prolyl-Hydroxylase Inhibitors*

Substances

Prolyl-Hydroxylase Inhibitors
Hypoxia-Inducible Factor-Proline Dioxygenases